Join Growin Stock Community!
Beta
Back to PFE.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
net-income-chart

PFE Net Income

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

The latest data point for Pfizer's (PFE) net income in Q1'26 shows a positive figure of $2.69B USD, marking a recovery from the previous quarter's loss and contributing to an overall stabilization in recent performance. Over the period from Q2'23 to Q1'26, net income exhibited significant volatility, starting with a profit of $2.33B USD in Q2'23 before plunging into consecutive losses totaling -$5.75B USD across Q3'23 and Q4'23, followed by a rebound to $4.47B USD in Q3'24. Subsequent quarters displayed mixed results, including a sharp Q4'25 loss of -$1.65B USD, with year-over-year changes ranging from a dramatic +70% growth in Q2'25 to steep declines like -167% in Q4'23, highlighting underlying operational challenges and recoveries in the pharmaceutical sector. The bar chart underscores these fluctuations, while the overlaid YoY line reveals inconsistent growth momentum, with recent periods showing modest negative shifts around -9% in Q1'26.